Target Price | $20.91 |
Price | $5.80 |
Potential |
260.52%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Entrada Therapeutics 2026 .
The average Entrada Therapeutics target price is $20.91.
This is
260.52%
register free of charge
$22.05
280.17%
register free of charge
$20.20
248.28%
register free of charge
|
|
A rating was issued by 10 analysts: 9 Analysts recommend Entrada Therapeutics to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Entrada Therapeutics stock has an average upside potential 2026 of
260.52%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 210.78 | 47.72 |
63.38% | 77.36% | |
EBITDA Margin | 24.09% | -288.69% |
9,812.63% | 1,298.31% | |
Net Margin | 31.14% | -256.48% |
700.44% | 923.72% |
6 Analysts have issued a sales forecast Entrada Therapeutics 2025 . The average Entrada Therapeutics sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Entrada Therapeutics EBITDA forecast 2025. The average Entrada Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Entrada Therapeutics Analysts have issued a net profit forecast 2025. The average Entrada Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 1.68 | -3.23 |
940.00% | 292.26% | |
P/E | negative | |
EV/Sales | negative |
6 Analysts have issued a Entrada Therapeutics forecast for earnings per share. The average Entrada Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Entrada Therapeutics...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 20 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 04 2025 |
Roth MKM |
Locked
➜
Locked
|
Locked | Dec 05 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
Oppenheimer |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 20 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 25 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 04 2025 |
Locked
Roth MKM:
Locked
➜
Locked
|
Dec 05 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 06 2024 |
Locked
Oppenheimer:
Locked
➜
Locked
|
Nov 06 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.